Long-Term Effectiveness, Safety, and Predictive Factors of Tralokinumab Response in Adolescents with Atopic Dermatitis: Insights from a Real-World Multicenter Cohort.

INTRODUCTION: Atopic dermatitis (AD) is a common chronic inflammatory disease during adolescence, with severe forms having a particularly high impact on patients' quality of life. Several therapeutic options are currently approved for the treatment of AD in individuals over 12 years of age. Thi...

Descripción completa

Detalles Bibliográficos
Autores: Villodre Lozano P, Díaz Corpas T, Esteve Martínez A, Millán Parrilla F, Évole Buselli M, Martín Hernández JM, Berbegal de Gracia L, Melgosa Ramos FJ, Auban Pariente J, Sánchez Arraez J
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p19403
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/19403
Access Level:acceso abierto
Palabra clave:Adolescent patients
Atopic dermatitis
Obesity
Palmoplantar
Tralokinumab
id ES_8bc5cb4f00382b242822e65cd9cdcc03
oai_identifier_str oai:fisabio.fundanetsuite.com:p19403
network_acronym_str ES
network_name_str España
repository_id_str
spelling Long-Term Effectiveness, Safety, and Predictive Factors of Tralokinumab Response in Adolescents with Atopic Dermatitis: Insights from a Real-World Multicenter Cohort.Villodre Lozano PDíaz Corpas TEsteve Martínez AMillán Parrilla FÉvole Buselli MMartín Hernández JMBerbegal de Gracia LMelgosa Ramos FJAuban Pariente JSánchez Arraez JAdolescent patientsAtopic dermatitisObesityPalmoplantarTralokinumabINTRODUCTION: Atopic dermatitis (AD) is a common chronic inflammatory disease during adolescence, with severe forms having a particularly high impact on patients' quality of life. Several therapeutic options are currently approved for the treatment of AD in individuals over 12 years of age. This study evaluated the efficacy and safety of tralokinumab in adolescent patients, with a particular focus on identifying which patient profiles may derive the greatest benefit from this therapy. METHODS: A retrospective multicenter study was conducted across nine Spanish hospitals, including patients from 12 to 17 years old with moderate-to-severe AD treated with tralokinumab. RESULTS: A total of 27 patients were included, with a mean age of 14.8 years. Nine had previously received treatment with dupilumab, five due to primary or secondary failure, and four due to adverse events. One patient had been treated with upadacitinib, which was discontinued because of primary failure and acne. A statistically significant reduction was achieved in Eczema Area and Severity Index (EASI), pruritus visual analog scale (VAS), and Investigator's Global Assessment (IGA) scores. Palmoplantar involvement was observed in 44.4% of patients; after 24 weeks of treatment, 83.3% of those with palmoplantar involvement experienced complete resolution. Additionally, 37.0% of patients were overweight or obese, with no statistically significant differences in treatment efficacy. CONCLUSION: Tralokinumab demonstrated efficacy and safety in the treatment of moderate-to-severe AD in patients aged 12-17 years. Notably, the treatment was effective in adolescent patients with palmoplantar involvement and/or obesity.ADIS INT LTD2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/19403Dermatology and TherapyISSN: 21938210ISSNe: 21909172reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p194032026-06-11T12:45:17Z
dc.title.none.fl_str_mv Long-Term Effectiveness, Safety, and Predictive Factors of Tralokinumab Response in Adolescents with Atopic Dermatitis: Insights from a Real-World Multicenter Cohort.
title Long-Term Effectiveness, Safety, and Predictive Factors of Tralokinumab Response in Adolescents with Atopic Dermatitis: Insights from a Real-World Multicenter Cohort.
spellingShingle Long-Term Effectiveness, Safety, and Predictive Factors of Tralokinumab Response in Adolescents with Atopic Dermatitis: Insights from a Real-World Multicenter Cohort.
Villodre Lozano P
Adolescent patients
Atopic dermatitis
Obesity
Palmoplantar
Tralokinumab
title_short Long-Term Effectiveness, Safety, and Predictive Factors of Tralokinumab Response in Adolescents with Atopic Dermatitis: Insights from a Real-World Multicenter Cohort.
title_full Long-Term Effectiveness, Safety, and Predictive Factors of Tralokinumab Response in Adolescents with Atopic Dermatitis: Insights from a Real-World Multicenter Cohort.
title_fullStr Long-Term Effectiveness, Safety, and Predictive Factors of Tralokinumab Response in Adolescents with Atopic Dermatitis: Insights from a Real-World Multicenter Cohort.
title_full_unstemmed Long-Term Effectiveness, Safety, and Predictive Factors of Tralokinumab Response in Adolescents with Atopic Dermatitis: Insights from a Real-World Multicenter Cohort.
title_sort Long-Term Effectiveness, Safety, and Predictive Factors of Tralokinumab Response in Adolescents with Atopic Dermatitis: Insights from a Real-World Multicenter Cohort.
dc.creator.none.fl_str_mv Villodre Lozano P
Díaz Corpas T
Esteve Martínez A
Millán Parrilla F
Évole Buselli M
Martín Hernández JM
Berbegal de Gracia L
Melgosa Ramos FJ
Auban Pariente J
Sánchez Arraez J
author Villodre Lozano P
author_facet Villodre Lozano P
Díaz Corpas T
Esteve Martínez A
Millán Parrilla F
Évole Buselli M
Martín Hernández JM
Berbegal de Gracia L
Melgosa Ramos FJ
Auban Pariente J
Sánchez Arraez J
author_role author
author2 Díaz Corpas T
Esteve Martínez A
Millán Parrilla F
Évole Buselli M
Martín Hernández JM
Berbegal de Gracia L
Melgosa Ramos FJ
Auban Pariente J
Sánchez Arraez J
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Adolescent patients
Atopic dermatitis
Obesity
Palmoplantar
Tralokinumab
topic Adolescent patients
Atopic dermatitis
Obesity
Palmoplantar
Tralokinumab
description INTRODUCTION: Atopic dermatitis (AD) is a common chronic inflammatory disease during adolescence, with severe forms having a particularly high impact on patients' quality of life. Several therapeutic options are currently approved for the treatment of AD in individuals over 12 years of age. This study evaluated the efficacy and safety of tralokinumab in adolescent patients, with a particular focus on identifying which patient profiles may derive the greatest benefit from this therapy. METHODS: A retrospective multicenter study was conducted across nine Spanish hospitals, including patients from 12 to 17 years old with moderate-to-severe AD treated with tralokinumab. RESULTS: A total of 27 patients were included, with a mean age of 14.8 years. Nine had previously received treatment with dupilumab, five due to primary or secondary failure, and four due to adverse events. One patient had been treated with upadacitinib, which was discontinued because of primary failure and acne. A statistically significant reduction was achieved in Eczema Area and Severity Index (EASI), pruritus visual analog scale (VAS), and Investigator's Global Assessment (IGA) scores. Palmoplantar involvement was observed in 44.4% of patients; after 24 weeks of treatment, 83.3% of those with palmoplantar involvement experienced complete resolution. Additionally, 37.0% of patients were overweight or obese, with no statistically significant differences in treatment efficacy. CONCLUSION: Tralokinumab demonstrated efficacy and safety in the treatment of moderate-to-severe AD in patients aged 12-17 years. Notably, the treatment was effective in adolescent patients with palmoplantar involvement and/or obesity.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/19403
url https://fisabio.portalinvestigacion.com/publicaciones/19403
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ADIS INT LTD
publisher.none.fl_str_mv ADIS INT LTD
dc.source.none.fl_str_mv Dermatology and Therapy
ISSN: 21938210
ISSNe: 21909172
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412850412290048
score 15,811543

Similares en LA Referencia